Pharmaceuticals
Carl Icahn claims Illumina directors got extra insurance to close ‘disastrous’ $7.1 billion Grail deal
Carl Icahn on Friday alleged that Illumina‘s directors demanded extra personal liability insurance before the biotech company signed off on a $7.1 billion acquisition of cancer test developer Grail in 2021. The claim is the latest development in a brewing proxy fight between the activist investor and San Diego-based Illumina, who have been trading jabs […]
Read More
Pfizer’s Covid drug Paxlovid may reduce the risk of developing long Covid, study says
A prescription for Pfizers Paxlovid tablets outside of his apartment in Philadelphia, Pennsylvania on April 25, 2022. (Photo by Rachel Wisniewski/For the Washington Post) Rachel Wisniewski | The Washington Post | Getty Images People who take Pfizer‘s Covid antiviral treatment Paxlovid shortly after infection may reduce their risk of developing long Covid, regardless of their […]
Read More
Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD
A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France June 15, 2022. Benoit Tessier | Reuters Shares of Sanofi and Regeneron both jumped by more than 6% on Thursday after the pharmaceutical companies released promising data showing their […]
Read More
Enjoy are living: TikTok CEO testifies in advance of Home committee as possible U.S. ban looms
(The stream is slated to commence at 10:00 a.m. ET. Be sure to refresh the web site if you do not see a video clip previously mentioned at that time.) TikTok CEO Shou Zi Chew will testify ahead of the Home Strength and Commerce Committee on Thursday morning as his business fights to stave off […]
Read More
FDA advisors vote against effectiveness of Biogen’s ALS drug for rare and aggressive form of the disease
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration’s independent panel of advisors on Wednesday voted against the effectiveness of Biogen’s investigational ALS drug for a rare and aggressive form of the disease. The drug tofersen […]
Read More
FDA advisors reject Biogen’s ALS drug for rare and aggressive form of the disease
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration’s independent panel of advisors on Wednesday declined to endorse accelerated approval of Biogen’s investigational ALS drug for a rare and aggressive form of the disease. The drug […]
Read More
View stay: Treasury Secretary Janet Yellen testifies at Senate hearing
(The stream is slated to begin at 2:30 pm ET. Remember to refresh the page if you do not see a online video above at that time.) Treasury Secretary Janet Yellen will testify just before the Senate Appropriations Committee Wednesday, where by she is most likely to deal with rough queries about the federal response […]
Read More
If you had Covid before you were vaccinated, you might have less immunity than you think, study says
A healthcare worker administers a dose of the Pfizer-BioNTech Covid-19 vaccine at a vaccination clinic in the Peabody Institute Library in Peabody, Massachusetts, U.S., on Wednesday, Jan. 26, 2022. Vanessa Leroy | Bloomberg | Getty Images People who caught Covid-19 before they were vaccinated had a weaker immune response to the shots than those who […]
Read More
FDA staff says Biogen’s ALS drug may have a ‘clinical benefit’ on a rare form of the disease
U.S. Food and Drug Administration staff on Monday said Biogen’s investigational ALS drug may have a “clinical benefit” on a rare and aggressive form of the disease, despite failing a broader late-stage clinical trial last year. The staff made the conclusion in briefing documents ahead of a meeting on Wednesday when a panel of external […]
Read More
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal
Carl Icahn Adam Jeffery | CNBC Biotech company Illumina pushed back Monday against Carl Icahn’s proxy fight over the company’s acquisition of cancer test developer Grail, saying the activist investor’s board nominees “do not add value.” The San Diego-based DNA sequencing company released its latest response to Icahn’s sharp criticism of the $7.1 billion deal […]
Read More